alanine has been researched along with Cancer of Prostate in 40 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated the association of prostate cancer with genetic polymorphisms in SOD1 (CuZn-SOD; IVS3-251A>G), SOD2 [MnSOD; Ex2+24T>C (V16A)], and SOD3 (EC-SOD; IVS1+186C>T, Ex3-631C>G, Ex3-516C>T, and Ex3-489C>T), the three main isoforms of SOD." | 2.73 | Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study. ( Berndt, SI; Chanock, S; Chatterjee, N; Hayes, RB; Huang, WY; Kang, D; Lee, KM; Park, SK; Peters, U; Reding, D; Welch, R, 2007) |
| "Odds ratios (ORs) for prostate cancer were estimated by unconditional logistic and polytomous regression." | 2.42 | ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer. ( Boyle, P; English, DR; Giles, GG; Hopper, JL; McCredie, MR; Morris, H; Neufing, P; Severi, G; Southey, MC; Tesoriero, A; Tilley, W, 2003) |
| "Overexpression of KIFC1 in prostate cancer (PCa) cells showed resistance to docetaxel (DTX)." | 1.56 | Inhibition of kinesin motor protein KIFC1 by AZ82 induces multipolar mitosis and apoptosis in prostate cancer cell. ( Hao, SL; Parvin, A; Tan, FQ; Yang, WX, 2020) |
| "Obesity is associated with increased incidence and worse prognosis of more than one dozen tumor types; however, the molecular mechanisms for this association remain under debate." | 1.51 | Obesity-associated, but not obesity-independent, tumors respond to insulin by increasing mitochondrial glucose oxidation. ( Perry, RJ; Rabin-Court, A; Rodrigues, MR; Zhang, XM, 2019) |
| "Sarcosine oxidase was shown to eliminate only sarcosine in the presence of D,L-alanine, and was consequently used as the selective enzyme." | 1.39 | Partial enzymatic elimination and quantification of sarcosine from alanine using liquid chromatography-tandem mass spectrometry. ( Burton, C; Gamagedara, S; Ma, Y, 2013) |
| "Diagnosis of prostate cancer by prostate specific antigen (PSA) is error-prone and cannot distinguish benign prostatic hyperplasia (BPH) from malignant disease, nor identify aggressive and indolent types." | 1.38 | Plasma sarcosine does not distinguish early and advanced stages of prostate cancer. ( Bohm, L; Bouic, PJ; Fernandez, P; Harvey, J; Serafin, AM; Van der Watt, G, 2012) |
| " In normal rats, Michaelis-Menten kinetics were able to describe the dose-response of the fitted exchange rate constants with a 13." | 1.36 | Kinetic modeling of hyperpolarized 13C1-pyruvate metabolism in normal rats and TRAMP mice. ( Albers, MJ; Bok, R; Chen, AP; Hurd, RE; Kurhanewicz, J; Nelson, SJ; Park, I; Tropp, J; Vigneron, DB; Yen, YF; Zhang, V; Zierhut, ML, 2010) |
| "In biopsies containing prostate cancer there was a highly significant (P < 0." | 1.35 | Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. ( Albers, MJ; Gribbestad, IS; Joun, D; Keshari, KR; Kurhanewicz, J; Nelson, SJ; Shinohara, K; Simko, JP; Swanson, MG; Tabatabai, ZL; Tessem, MB; Vigneron, DB, 2008) |
| "Ninety-one adult Caucasians with prostate cancer were recruited between 1994 and 1998." | 1.33 | Peroxisome proliferator-activated receptor-gamma polymorphism, body mass and prostate cancer risk: evidence for gene-environment interaction. ( Cauley, JA; Ferrell, RE; Modugno, F; Moffett, SP; Trump, DL; Weissfeld, JL; Zmuda, JM, 2006) |
| "Three androgen-independent human prostate cancer cell lines (TSU-Prl, DU-145, and PC-3) were cultured in the presence of azatyrosine and their growth rates were determined over a 7-day period." | 1.29 | Reversion of human prostate tumorigenic growth by azatyrosine. ( Benoit, RM; Eiseman, J; Jacobs, SC; Kyprianou, N, 1995) |
| "Seven patients were diagnosed with prostate cancer, 13 with benign prostatic hypertrophy, and 3 with both conditions." | 1.28 | Differentiation of human prostate cancer from benign hypertrophy by in vitro 1H NMR. ( Dalrymple, GV; Finkbeiner, AE; Fowler, AH; Holder, JC; Komoroski, RA; Mullins, MS; Pappas, AA; Sprigg, JR, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.50) | 18.7374 |
| 1990's | 4 (10.00) | 18.2507 |
| 2000's | 17 (42.50) | 29.6817 |
| 2010's | 16 (40.00) | 24.3611 |
| 2020's | 2 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, X | 1 |
| Xia, B | 1 |
| Zheng, H | 1 |
| Ning, J | 1 |
| Zhu, Y | 1 |
| Shao, X | 1 |
| Liu, B | 1 |
| Dong, B | 1 |
| Gao, H | 1 |
| Parvin, A | 1 |
| Hao, SL | 1 |
| Tan, FQ | 1 |
| Yang, WX | 1 |
| Roviello, GN | 2 |
| Iannitti, R | 2 |
| Palumbo, R | 2 |
| Simonyan, H | 2 |
| Vicidomini, C | 2 |
| Roviello, V | 2 |
| Li, P | 1 |
| Chen, J | 1 |
| Kashiwagi, E | 1 |
| Mizushima, T | 1 |
| Han, B | 1 |
| Inoue, S | 1 |
| Ide, H | 1 |
| Izumi, K | 1 |
| Miyamoto, H | 1 |
| Ii, H | 1 |
| Yoshiya, T | 1 |
| Nakata, S | 1 |
| Taniguchi, K | 1 |
| Hidaka, K | 1 |
| Tsuda, S | 1 |
| Mochizuki, M | 1 |
| Nishiuchi, Y | 1 |
| Tsuda, Y | 1 |
| Ito, K | 1 |
| Kageyama, S | 1 |
| Yoshiki, T | 1 |
| Milshteyn, E | 1 |
| von Morze, C | 2 |
| Gordon, JW | 1 |
| Zhu, Z | 1 |
| Larson, PEZ | 1 |
| Vigneron, DB | 5 |
| Rabin-Court, A | 1 |
| Rodrigues, MR | 1 |
| Zhang, XM | 1 |
| Perry, RJ | 1 |
| DePorter, SM | 1 |
| Lui, I | 1 |
| Bruce, VJ | 1 |
| Gray, MA | 1 |
| Lopez-Islas, M | 1 |
| McNaughton, BR | 1 |
| McGoldrick, CA | 1 |
| Jiang, YL | 1 |
| Brannon, M | 1 |
| Krishnan, K | 1 |
| Stone, WL | 1 |
| Carlucci, G | 1 |
| Kuipers, A | 1 |
| Ananias, HJ | 1 |
| de Paula Faria, D | 1 |
| Dierckx, RA | 1 |
| Helfrich, W | 1 |
| Rink, R | 1 |
| Moll, GN | 1 |
| de Jong, IJ | 1 |
| Elsinga, PH | 1 |
| Tessem, MB | 1 |
| Swanson, MG | 1 |
| Keshari, KR | 1 |
| Albers, MJ | 3 |
| Joun, D | 1 |
| Tabatabai, ZL | 1 |
| Simko, JP | 1 |
| Shinohara, K | 1 |
| Nelson, SJ | 3 |
| Gribbestad, IS | 1 |
| Kurhanewicz, J | 3 |
| Bok, R | 3 |
| Chen, AP | 2 |
| Cunningham, CH | 1 |
| Zierhut, ML | 2 |
| Zhang, VY | 1 |
| Kohler, SJ | 1 |
| Tropp, J | 2 |
| Hurd, RE | 2 |
| Yen, YF | 2 |
| Anton, M | 2 |
| Wagner, D | 2 |
| Selbach, HJ | 1 |
| Hackel, T | 1 |
| Hermann, RM | 2 |
| Hess, CF | 2 |
| Vorwerk, H | 2 |
| Zhang, V | 1 |
| Park, I | 1 |
| Leisvuori, A | 1 |
| Aiba, Y | 1 |
| Lönnberg, T | 1 |
| Poijärvi-Virta, P | 1 |
| Blatt, L | 1 |
| Beigelman, L | 1 |
| Lönnberg, H | 1 |
| Reed, G | 1 |
| Shin, P | 1 |
| Larson, PE | 1 |
| Hu, S | 1 |
| Bohm, L | 1 |
| Serafin, AM | 1 |
| Fernandez, P | 1 |
| Van der Watt, G | 1 |
| Bouic, PJ | 1 |
| Harvey, J | 1 |
| Vaz, CV | 1 |
| Alves, MG | 1 |
| Marques, R | 1 |
| Moreira, PI | 1 |
| Oliveira, PF | 1 |
| Maia, CJ | 1 |
| Socorro, S | 1 |
| Burton, C | 1 |
| Gamagedara, S | 1 |
| Ma, Y | 1 |
| James, AJ | 1 |
| Agoulnik, IU | 1 |
| Harris, JM | 1 |
| Buchanan, G | 1 |
| Tilley, WD | 1 |
| Marcelli, M | 1 |
| Lamb, DJ | 1 |
| Weigel, NL | 1 |
| Li, Y | 1 |
| Raffo, AJ | 1 |
| Drew, L | 1 |
| Mao, Y | 1 |
| Tran, A | 1 |
| Petrylak, DP | 1 |
| Fine, RL | 1 |
| Severi, G | 1 |
| Giles, GG | 1 |
| Southey, MC | 1 |
| Tesoriero, A | 1 |
| Tilley, W | 1 |
| Neufing, P | 1 |
| Morris, H | 1 |
| English, DR | 1 |
| McCredie, MR | 1 |
| Boyle, P | 1 |
| Hopper, JL | 1 |
| Fornaro, M | 1 |
| Plescia, J | 1 |
| Chheang, S | 1 |
| Tallini, G | 1 |
| Zhu, YM | 1 |
| King, M | 1 |
| Altieri, DC | 1 |
| Languino, LR | 1 |
| Song, JJ | 1 |
| Lee, YJ | 1 |
| Stone, A | 1 |
| Ratnasinghe, LD | 1 |
| Emerson, GL | 1 |
| Modali, R | 1 |
| Lehman, T | 1 |
| Runnells, G | 1 |
| Carroll, A | 1 |
| Carter, W | 1 |
| Barnhart, S | 1 |
| Rasheed, AA | 1 |
| Greene, G | 1 |
| Johnson, DE | 1 |
| Ambrosone, CB | 1 |
| Kadlubar, FF | 1 |
| Lang, NP | 1 |
| Taufer, M | 1 |
| Peres, A | 1 |
| de Andrade, VM | 1 |
| de Oliveira, G | 1 |
| Sá, G | 1 |
| do Canto, ME | 1 |
| dos Santos, AR | 1 |
| Bauer, ME | 1 |
| da Cruz, IB | 1 |
| Giwercman, YL | 1 |
| Abrahamsson, PA | 1 |
| Giwercman, A | 1 |
| Gadaleanu, V | 1 |
| Ahlgren, G | 1 |
| Yin, S | 1 |
| Li, X | 2 |
| Meng, Y | 1 |
| Finley, RL | 1 |
| Sakr, W | 1 |
| Yang, H | 1 |
| Reddy, N | 1 |
| Sheng, S | 1 |
| Guan, B | 1 |
| Maghami, S | 1 |
| Bieberich, CJ | 1 |
| Zmuda, JM | 1 |
| Modugno, F | 1 |
| Weissfeld, JL | 1 |
| Cauley, JA | 1 |
| Trump, DL | 1 |
| Moffett, SP | 1 |
| Ferrell, RE | 1 |
| Kang, D | 1 |
| Lee, KM | 1 |
| Park, SK | 1 |
| Berndt, SI | 1 |
| Peters, U | 1 |
| Reding, D | 1 |
| Chatterjee, N | 1 |
| Welch, R | 1 |
| Chanock, S | 1 |
| Huang, WY | 1 |
| Hayes, RB | 1 |
| Liu, L | 1 |
| He, B | 1 |
| Liu, WM | 1 |
| Zhou, D | 1 |
| Cox, JV | 1 |
| Zhang, XA | 1 |
| Gsänger, T | 1 |
| Christiansen, H | 1 |
| Poppe, B | 1 |
| Benoit, RM | 1 |
| Eiseman, J | 1 |
| Jacobs, SC | 1 |
| Kyprianou, N | 1 |
| Berrevoets, CA | 1 |
| Veldscholte, J | 1 |
| Mulder, E | 1 |
| Suzuki, H | 1 |
| Sato, N | 1 |
| Watabe, Y | 1 |
| Masai, M | 1 |
| Seino, S | 1 |
| Shimazaki, J | 1 |
| Fowler, AH | 1 |
| Pappas, AA | 1 |
| Holder, JC | 1 |
| Finkbeiner, AE | 1 |
| Dalrymple, GV | 1 |
| Mullins, MS | 1 |
| Sprigg, JR | 1 |
| Komoroski, RA | 1 |
| Sugiura, H | 1 |
| Shimaya, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1 Ascending-dose Study to Assess the Safety and Tolerability and Imaging Potential of Hyperpolarized Pyruvate (13C) Injection in Subjects With Prostate Cancer[NCT01229618] | Phase 1 | 31 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Hyperpolarized 13-C Pyruvate MRI Surveillance of Multiple Cancers[NCT05697406] | Phase 1/Phase 2 | 25 participants (Anticipated) | Interventional | 2024-02-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for alanine and Cancer of Prostate
| Article | Year |
|---|---|
ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer.
Topics: Aged; Alanine; Case-Control Studies; Genetic Predisposition to Disease; Heterozygote; Homozygote; Hu | 2003 |
1 trial available for alanine and Cancer of Prostate
| Article | Year |
|---|---|
Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study.
Topics: Aged; Alanine; Alleles; Antioxidants; Case-Control Studies; Diet; Exons; Free Radical Scavengers; Ge | 2007 |
38 other studies available for alanine and Cancer of Prostate
| Article | Year |
|---|---|
Identification of characteristic metabolic panels for different stages of prostate cancer by
Topics: Acetone; Alanine; Cross-Sectional Studies; Humans; Magnetic Resonance Spectroscopy; Male; Metabolomi | 2022 |
Inhibition of kinesin motor protein KIFC1 by AZ82 induces multipolar mitosis and apoptosis in prostate cancer cell.
Topics: Alanine; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Centrosome; Dyneins; Humans | 2020 |
Lac-L-TTA, a novel lactose-based amino acid-sugar conjugate for anti-metastatic applications.
Topics: Alanine; Amino Acids; Antineoplastic Agents; Cell Proliferation; Colony-Forming Units Assay; Humans; | 2017 |
The interaction between androgen receptor and semenogelin I: a synthetic LxxLL peptide antagonist inhibits the growth of prostate cancer cells.
Topics: Alanine; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chlorides; Dihydrotestosterone; Humans | 2018 |
A Novel Prodrug of a γ-Glutamylcyclotransferase Inhibitor Suppresses Cancer Cell Proliferation in vitro and Inhibits Tumor Growth in a Xenograft Mouse Model of Prostate Cancer.
Topics: Alanine; Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cell Proliferation; Dipeptides | 2018 |
High spatiotemporal resolution bSSFP imaging of hyperpolarized [1-
Topics: Adenocarcinoma; Alanine; Animals; Carbon Isotopes; Image Processing, Computer-Assisted; Lactic Acid; | 2018 |
Obesity-associated, but not obesity-independent, tumors respond to insulin by increasing mitochondrial glucose oxidation.
Topics: Alanine; Breast Neoplasms; Cell Line, Tumor; Citrate (si)-Synthase; Colonic Neoplasms; Female; Gene | 2019 |
Mutagenesis modulates the uptake efficiency, cell-selectivity, and functional enzyme delivery of a protein transduction domain.
Topics: Alanine; Amino Acid Sequence; Cell Line, Tumor; Humans; Male; Mutagenesis; Prostatic Neoplasms; Prot | 2014 |
In vitro evaluation of novel N-acetylalaninate prodrugs that selectively induce apoptosis in prostate cancer cells.
Topics: Alanine; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Membrane; Cell Survival; | 2014 |
GRPR-selective PET imaging of prostate cancer using [(18)F]-lanthionine-bombesin analogs.
Topics: Alanine; Animals; Bombesin; Cell Line, Tumor; Fluorine Radioisotopes; Humans; Male; Mice, Nude; Neop | 2015 |
[In Process Citation].
Topics: Alanine; Amino Acid Substitution; Cell Transformation, Neoplastic; DNA Mutational Analysis; Glycine; | 2015 |
Synthesis and biological evaluation of a novel Amadori compound.
Topics: Alanine; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Chemistry Techniques, Synthetic; Co | 2017 |
Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Biomarkers; Biomarkers, Tumor; Biopsy, Needle; Humans; Lact | 2008 |
Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading.
Topics: Adenocarcinoma; Alanine; Animals; Biomarkers, Tumor; Carbon Isotopes; Disease Models, Animal; Lactic | 2008 |
Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading.
Topics: Adenocarcinoma; Alanine; Animals; Biomarkers, Tumor; Carbon Isotopes; Disease Models, Animal; Lactic | 2008 |
Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading.
Topics: Adenocarcinoma; Alanine; Animals; Biomarkers, Tumor; Carbon Isotopes; Disease Models, Animal; Lactic | 2008 |
Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading.
Topics: Adenocarcinoma; Alanine; Animals; Biomarkers, Tumor; Carbon Isotopes; Disease Models, Animal; Lactic | 2008 |
In vivo dosimetry in the urethra using alanine/ESR during (192)Ir HDR brachytherapy of prostate cancer--a phantom study.
Topics: Alanine; Brachytherapy; Electron Spin Resonance Spectroscopy; Humans; Iridium Radioisotopes; Male; P | 2009 |
Kinetic modeling of hyperpolarized 13C1-pyruvate metabolism in normal rats and TRAMP mice.
Topics: Alanine; Algorithms; Animals; Carbon Isotopes; Computer Simulation; Kinetics; Lactic Acid; Magnetic | 2010 |
Chemical and enzymatic stability of amino acid derived phosphoramidates of antiviral nucleoside 5'-monophosphates bearing a biodegradable protecting group.
Topics: Acetates; Alanine; Amides; Animals; Antiviral Agents; Cytidine Monophosphate; Enzyme Stability; Este | 2010 |
Multi-band frequency encoding method for metabolic imaging with hyperpolarized [1-(13)C]pyruvate.
Topics: Alanine; Algorithms; Animals; Carbon Isotopes; Computer Simulation; Image Processing, Computer-Assis | 2011 |
Plasma sarcosine does not distinguish early and advanced stages of prostate cancer.
Topics: Alanine; Biomarkers, Tumor; Gas Chromatography-Mass Spectrometry; Humans; Male; Neoplasm Staging; Pr | 2012 |
Androgen-responsive and nonresponsive prostate cancer cells present a distinct glycolytic metabolism profile.
Topics: Alanine; Androgens; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glucose; Glucose Trans | 2012 |
Partial enzymatic elimination and quantification of sarcosine from alanine using liquid chromatography-tandem mass spectrometry.
Topics: Alanine; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Humans; Male; Oxidatio | 2013 |
A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity.
Topics: Alanine; Animals; Binding Sites; Biological Transport; Cell Nucleus; COS Cells; Dihydrotestosterone; | 2002 |
Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143.
Topics: Adenocarcinoma; Alanine; Antibodies, Monoclonal; Apoptosis; Caspase 3; Caspase 8; Caspase 9; Caspase | 2003 |
Fibronectin protects prostate cancer cells from tumor necrosis factor-alpha-induced apoptosis via the AKT/survivin pathway.
Topics: Adenocarcinoma; Adenoviridae; Alanine; Apoptosis; Caspases; Cell Adhesion; Cell Death; Cell Line; Ce | 2003 |
Tryptophan 621 and serine 667 residues of Daxx regulate its nuclear export during glucose deprivation.
Topics: Active Transport, Cell Nucleus; Alanine; Antibiotics, Antineoplastic; Binding Sites; Cell Line, Tumo | 2004 |
CYP3A43 Pro(340)Ala polymorphism and prostate cancer risk in African Americans and Caucasians.
Topics: Adult; Aged; Alanine; Arkansas; Aryl Hydrocarbon Hydroxylases; Black or African American; Genotype; | 2005 |
Is the Val16Ala manganese superoxide dismutase polymorphism associated with the aging process?
Topics: Adult; Aged; Aged, 80 and over; Aging; Alanine; Antigens, CD; Breast Neoplasms; Cause of Death; DNA | 2005 |
The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Aged; Alanine; Alleles; Arginine; Biomarkers, Tumor; Case-Con | 2005 |
Tumor-suppressive maspin regulates cell response to oxidative stress by direct interaction with glutathione S-transferase.
Topics: Alanine; Arginine; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Separation; DNA, Comp | 2005 |
NKX3.1 is regulated by protein kinase CK2 in prostate tumor cells.
Topics: Alanine; Amino Acid Sequence; Amino Acid Substitution; Animals; Apigenin; Blotting, Western; Casein | 2006 |
Peroxisome proliferator-activated receptor-gamma polymorphism, body mass and prostate cancer risk: evidence for gene-environment interaction.
Topics: Adult; Aged; Alanine; Body Mass Index; Case-Control Studies; Genotype; Humans; Insulin; Male; Middle | 2006 |
Tetraspanin CD151 promotes cell migration by regulating integrin trafficking.
Topics: Alanine; Amino Acid Motifs; Amino Acid Sequence; Amino Acid Substitution; Animals; Cell Line, Tumor; | 2007 |
In vivo alanine/electron spin resonance (ESR) dosimetry in radiotherapy of prostate cancer: a feasibility study.
Topics: Alanine; Electron Spin Resonance Spectroscopy; Feasibility Studies; Humans; Male; Prostatic Neoplasm | 2008 |
Reversion of human prostate tumorigenic growth by azatyrosine.
Topics: Adenocarcinoma; Alanine; Animals; Antibiotics, Antineoplastic; Cell Division; Cell Transformation, N | 1995 |
Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors.
Topics: Adenocarcinoma; Alanine; Amino Acid Sequence; Androgen Antagonists; Anilides; Animals; Blotting, Wes | 1993 |
Androgen receptor gene mutations in human prostate cancer.
Topics: Adenocarcinoma; Alanine; Amino Acid Sequence; Base Sequence; DNA Primers; DNA-Binding Proteins; DNA, | 1993 |
Differentiation of human prostate cancer from benign hypertrophy by in vitro 1H NMR.
Topics: Alanine; Citrates; Creatine; Glutamates; Glutamic Acid; Humans; In Vitro Techniques; Magnetic Resona | 1992 |
[Clinical application of "PPC" to prostatic hypertrophy and others].
Topics: Alanine; Capsules; Glutamates; Glycine; Humans; Male; Prostatic Diseases; Prostatic Hyperplasia; Pro | 1969 |